Rhenium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer. (EPIC-Skin)

  • End date
    May 15, 2024
  • participants needed
  • sponsor
    OncoBeta Therapeutics
Updated on 20 April 2022


Efficacy of Personalised Irradiation with Rhenium-Skin Cancer Therapy (SCT) for the treatment of non-melanoma skin cancer; a phase IV multi-centre, international, open label, single arm study.

Condition Non-melanoma Skin Cancer
Treatment Rhenium-SCT
Clinical Study IdentifierNCT05135052
SponsorOncoBeta Therapeutics
Last Modified on20 April 2022


Yes No Not Sure

Inclusion Criteria

Stage I or II BCC or SCC (SCC Well to Moderately Differentiated), and clinically node negative disease
Confirmed Histology, and with depth of lesion noted
Subjects with up to 3 lesions suitable to enter the study (subjects with more than 3 lesions are not excluded from the study, however 3 target lesions are determined for study evaluation only.)
Subjects able and willing to comply with the requirements of the study
Age >=18 years
Informed Consent signed by the subject consenting to undergo the study
Lesions up to 8cm2
Lesions with a depth up to 3mm confirmed on biopsy report AND deemed appropriate clinically by treating clinician
Subjects who are not deemed suitable for surgery, for example due to tumour location, performance status or other comorbidities as deemed relevant by the treating clinician
Patients who may have declined Surgery and/or fractionated Radiation Therapy

Exclusion Criteria

Inability to personally provide written informed consent or to understand and collaborate throughout the study
Inability or unwillingness to comply with study requirements
Prior treatment with surgery or radiation therapy for their target lesion(s)
Depth of lesion greater than 3mm as defined by Biopsy and/or clinical assessment
Lupus and Scleroderma
Basal cell naevus syndrome, xeroderma, vitiligo and albinism
Prior laser at the tumour site
Malignant melanoma systemic therapy ongoing
Any ongoing treatment for malignancy, or in the last 4 weeks prior to study entry
A tumour affecting nerves or bony structures
Clinical concern of metastatic disease
Pregnancy and/or Lactation
Pathological exclusions: Perineural Invasion, Lymphovascular invasion
Anatomical exclusions: NMSC's of the Medial canthus, eyelid margin (upper and lower), Vermillion lip
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note